Aerie Pharmaceuticals

Aerie Pharmaceuticals is an ophthalmic pharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for various eye diseases, including glaucoma, dry eye, and retinal conditions. The company’s notable products include Rhopressa, a once-daily eye drop designed to lower elevated intraocular pressure in patients with glaucoma or ocular hypertension, and Rocklatan, a fixed-dose combination of Rhopressa and latanoprost for treating open-angle glaucoma and ocular hypertension. Additionally, Aerie is developing several clinical-stage candidates, including AVX-012 for dry eye and AR-1105 and AR-13503, which are sustained-release implants aimed at retinal diseases. The company was founded in 2005 and is headquartered in Durham, North Carolina, with research facilities located in Research Triangle Park. Aerie Pharmaceuticals has also established collaborative agreements for research and development initiatives.

David Epstein

Co-Founder

1 past transactions

AVX Pharma

Acquisition in 2019
AVX Pharma is a biopharmaceutical company dedicated to developing innovative treatments for significant ophthalmic unmet medical needs, particularly ocular surface diseases. Founded in July 2013, the company emerged from neurobiological research led by Professor Carlos Belmonte at the Instituto de Neurociencias de Alicante. Based in Barcelona, AVX Pharma specializes in creating advanced medicinal products aimed at improving recovery times for conditions such as dry eye syndrome, thereby enhancing patient outcomes in the field of ophthalmology.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.